67 phenotypes from 2 alleles in 2 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Mark2Gt(pSABetageo)38Bss/Mark2+ involves: 129S2/SvPas * MF1	decreased body weight	J:57958
	postnatal growth retardation	J:57958
Mark2Gt(pSABetageo)38Bss/Mark2Gt(pSABetageo)38Bss involves: 129S2/SvPas * MF1	decreased body weight	J:57958
	decreased circulating progesterone level	J:57958
	decreased circulating prolactin level	J:57958
	decreased corpora lutea number	J:57958
	decreased epididymis weight	J:57958
	decreased ovary weight	J:57958
	decreased seminal vesicle weight	J:57958
	decreased testis weight	J:57958
	decreased uterus weight	J:57958
	enlarged heart	J:57958
	enlarged lung	J:57958
	increased brain size	J:57958
	increased prolactin level	J:57958
	infertility	J:57958
	postnatal growth retardation	J:57958
	reduced female fertility	J:57958
	small pituitary gland	J:57958
Mark2tm1Hpw/Mark2+ involves: 129X1/SvJ * C57BL/6	decreased body weight	J:120128
	hemoglobinuria	J:68830
	increased urine protein level	J:68830
	rectal prolapse	J:68830
Mark2tm1Hpw/Mark2tm1Hpw involves: 129X1/SvJ * C57BL/6	abnormal CD4-positive, alpha beta T cell morphology	J:68830
	abnormal eating behavior	J:120128
	abnormal glomerular capillary morphology	J:68830
	abnormal glucose homeostasis	J:120128
	abnormal humoral immune response	J:68830
	abnormal immune system physiology	J:68830
	abnormal spleen B cell follicle morphology	J:68830
	decreased B cell proliferation	J:68830
	decreased body length	J:120128
	decreased body weight	J:68830, J:120128
	decreased brown adipose tissue amount	J:120128, J:163905
	decreased circulating adiponectin level	J:163905
	decreased circulating cholesterol level	J:120128
	decreased circulating insulin level	J:120128
	decreased circulating insulin-like growth factor I level	J:120128
	decreased circulating leptin level	J:120128
	decreased circulating triglyceride level	J:120128
	decreased embryo weight	J:120128
	decreased IgG3 level	J:68830
	decreased IgM level	J:68830
	decreased litter size	J:68830
	decreased percent body fat/body weight	J:120128
	decreased susceptibility to age-related hepatic steatosis	J:120128
	decreased susceptibility to diet-induced obesity	J:120128
	decreased susceptibility to weight gain	J:163905
	decreased white adipose tissue amount	J:120128, J:163905
	enlarged lymph nodes	J:68830
	enlarged spleen	J:68830
	glomerulonephritis	J:68830
	hemoglobinuria	J:68830
	hypoglycemia	J:120128
	improved glucose tolerance	J:120128
	increased adipocyte glucose uptake	J:120128
	increased B cell number	J:68830
	increased B cell proliferation	J:68830
	increased basal metabolism	J:120128
	increased energy expenditure	J:120128
	increased insulin sensitivity	J:120128
	increased interferon-gamma secretion	J:68830
	increased interleukin-4 secretion	J:68830
	increased mesangial cell number	J:68830
	increased renal glomerulus lobularity	J:68830
	increased spleen weight	J:68830
	increased urine protein level	J:68830
	kidney inflammation	J:68830
	lung inflammation	J:68830
	lymph node hyperplasia	J:68830
	postnatal growth retardation	J:68830
	postnatal lethality, incomplete penetrance	J:68830
	rectal prolapse	J:68830
	salivary gland inflammation	J:68830
	spleen hyperplasia	J:68830